Obesity Management

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

As the age of diagnosis for pre and type 2 diabetes continues to decrease, Dr. Tina Thethi believes in focusing on reducing risk factors to prevent further complications.

The ongoing buzz around GLP-1 RAs, like semaglutide, and now the GIP combination drug tirzepatide, reached a summit at Pri-Med Midwest 2022.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

Semaglutide (Wegovy) has drawn attention for its indication of weight loss. Recently, however, the focus has shifted to the data surrounding tirzepatide.

Despite the efforts to increase the affordability of GLP-1 receptor agonists cost-effectiveness is still a barrier for many patients living with diabetes looking for effective therapies.

Primary Care Physicians (PCPs) play a crucial role in endorsing lifestyle counseling and facilitating integrative care for their patients.

"Less than 2 or 3% of individuals with obesity—who are candidates for pharmacotherapy—actually receive a medication," Dr. Robert Kushner explains in an interview.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

A conversation on advancements in diabetes, the rising cost of insulin, and advice regarding disease management.

Early time-restricted eating was more effective for losing weight than eating over a window of ≥12 hours, but did not affect body fat.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Trends in adjusted obesity prevalence increased over 20 years, particularly in adolescents from low-socioeconomic status households.

Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.

Vaccine effectiveness was slightly lower in patients with underweight, who also have the lowest levels of vaccine uptake across all ages.

The approval, which was was supported by data from a 56-week trial involving 223 obese individuals 12-17 years old, recommended the capsules be used in conjunction with a reduced-calorie diet and increased physical activity.

A look into the top discussions on the management of obesity at the 2022 OMA Spring Meeting, from new agents to treating special populations.

Dr. Auriemma examines recent paradigm shifts in obesity care, from new pharmacotherapy options to the important role of stakeholders in reducing rates.

Patients with obesity who had bariatric surgery had lower rates of mortality compared to patients who did not have bariatric surgery.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

The FDA-approved sleep agent was associated with ≥5% weight loss in more than one-quarter of patients in a phase 3 trial.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.